LLY
Eli Lilly and Company
LLY has the edge over ZYME overall, supported by stronger valuation and stronger fundamentals.
ZYME
Zymeworks Inc.
ZYME trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ZYME Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Weak | |
| Weak |
ZYME's revenue and profitability are currently healthy, but its cash flow and balance sheet are weak.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over ZYME in the historical PE scenario, which offers more potential upside but is not a forecast.
ZYME PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 2.6x | $1.33 | -95% |
| Fair | 3.2x | $1.65 | -94% |
| Expensive | 4.5x | $2.34 | -91% |
| Forward | 49x | $26.47 | — |
| Current | 51x | $26.47 | — |
Historical ranges are pointers, not guarantees.
ZYME's PE is in its expensive range at 51x. On analysts' estimates for next year's earnings, today's price would be 49x.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over ZYME on the outlook, with more favorable valuation and earnings expectations.
ZYME Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Strong decline | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect ZYME's revenue to grow, but its earnings and profitability to decline. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ZYME on earnings, with more consistent year-over-year improvement.
ZYME Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.54 | +4.1% |
| Q3 2026 | $0.52 | +$1.37 |
| Q2 2026 | -$2.02 | -$1.04 |
| Q1 2026 | -$1.37 | +$0.13 |
| Q4 2025 | -$1.08 | +$0.54 |
| Q3 2025 | -$0.85 | +$0.63 |
| Q2 2025 | -$0.98 | +$0.52 |
| Q1 2025 | -$1.50 | +$0.27 |
| Q4 2024 | -$1.62 | +$0.10 |
ZYME has returned to profit: it earned $0.52 per share over the past year, after losing money the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
ZYME Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $256.5M | +829% |
| Q2 2026 | $4.6M | -91% |
| Q1 2026 | $2.4M | -91% |
| Q4 2025 | $2.5M | -92% |
| Q3 2025 | $27.6M | +73% |
| Q2 2025 | $48.7M | +153% |
| Q1 2025 | $27.1M | +170% |
| Q4 2024 | $31M | +83% |
ZYME's revenue is recovering but still below its 2022 peak: $256M last quarter, up 829% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 69% | +149 points |
| Q2 2026 | -919% | -918 points |
| Q1 2026 | -1957% | -1862 points |
| Q4 2025 | -1756% | -1684 points |
| Q3 2025 | -80% | +134 points |
| Q2 2025 | -1.4% | +222 points |
| Q1 2025 | -94% | +282 points |
| Q4 2024 | -72% | +67 points |
ZYME has the edge over LLY on profitability, with a higher operating margin.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ZYME on cash generation, producing positive trailing cash flow while its opponent burns cash.
ZYME Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$24.1M | +$7.7M |
| Q2 2026 | -$31.9M | -376% |
| Q1 2026 | -$45.9M | -$42.5M |
| Q4 2025 | -$10.8M | +$31M |
| Q3 2025 | -$31.8M | -$25M |
| Q2 2025 | $11.6M | +$37.1M |
| Q1 2025 | -$3.4M | +$34.4M |
| Q4 2024 | -$41.8M | -408% |
ZYME has burned cash in almost every quarter: −$113M over the past year, against −$66M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ZYME on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ZYME Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.5% | +3.3M shares |
| 1 year | +0.6% | +477K shares |
| 3 years | +8% | +5.7M shares |
| 5 years | +46% | +24M shares |
| Available history | +101% | +38.2M shares |
ZYME has 76M diluted shares, up 0.6% from a year ago, despite $166M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $12M |
| Q2 2026 | $51.9M |
| Q1 2026 | $76.2M |
| Q4 2025 | $25.5M |
| Q4 2024 | $9.4M |
ZYME spent $166M buying back its own shares over the past year.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over ZYME on leverage, with a lower net debt burden relative to earnings.
ZYME Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.9x | High |
ZYME's net debt is about 4.8 years of its operating earnings (EBITDA).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ZYME Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.4 | Neutral |
| Stochastic | 63.0 | Neutral |
ZYME's weekly RSI is 51 (neutral) and its Stochastic is 63 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over ZYME on valuation relative to its sector.
ZYME PE vs Healthcare Sector
| Metric | ZYME | Sector median | Relative |
|---|---|---|---|
| PE | 51x | 26x | 97% above |
| PE % | 100 | 29 | 71 pts above |
ZYME is trading at 51x earnings, a 97% premium to the Healthcare sector's median of 26x.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ZYME on trend strength, trading above more of its moving averages.
ZYME Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $26.9 | 1.7% below |
| 20 week MA | $26.2 | 1% above |
| 50 week MA | $25.3 | 4.8% above |
| 100 week MA | $19.9 | 33% above |
| 200 week MA | $14.8 | 79% above |
ZYME's trend is up, with a small recent dip: it's below only its 8-week average, and 79% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ZYME on returns for 2026, with the stronger performance.
ZYME Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.7 | $50.1 | +12% |
| 2021 | $50.1 | $16.6 | -67% |
| 2022 | $16.6 | $8.04 | -51% |
| 2023 | $8.04 | $10.4 | +29% |
| 2024 | $10.4 | $14.5 | +40% |
| 2025 | $14.5 | $26.9 | +85% |
| 2026 YTD | $26.9 | $26.5 | -1.5% |
ZYME has finished higher in four of the last six years. It's down 1.5% so far in 2026.